[STUDY_ID_REMOVED] 
 
Study ID: 199201‐009 
 
 
Title: A Phase 2, Multicenter, Double‐masked, Randomized, Vehicle‐Controlled, Study of the Concurrent 
Use of AGN‐190584 and AGN‐199201 in Patients With Presbyopia  
 
Statistical Analysis Plan Amendment 2 Date : 09Nov2017 
 
  
 
1. Title Page 
STATISTICAL ANALYSIS PLAN 
 
A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the 
Concurrent Use of AGN-190584 and AGN-199201  in Patients with Presbyopia  
 
Amendment 2.0: 2017-11-09  
 
Study Number: 199201-009 
Development Phase: 2b 
Product Name: AGN-199201 (oxymetazoline hydrochloride 
ophthalmic solution) and AGN-190584 (pilocarpine 
hydrochloride ophthalmic solution) 
Study Statistician:  
Sponsor: Allergan (North America) 
2525 Dupont Drive, Irvine, California USA 92612 
 
 This document is the property of Allergan PL C and may not, in full or part, be passed on, 
reproduced, published, distributed to any person,  or submitted to any regulatory authority 
without the express written permission of Allergan PLC.

2. Table of Contents 
1. Title Page  .............................................................................................................................. ... 1 
2. Table of Contents  ..................................................................................................................... 2 
2.1 List of Tables  .................................................................................................................. 3 
2.2 List of Figures ................................................................................................................ 4 
3. List of Abbreviations and Definition of Terms  ........................................................................ 5 
4. Introduction  ..............................................................................................................................  6 
4.1 Study Design Summary  ................................................................................................. 6 
4.2 Study Objectives and Endpoints  .................................................................................... 7 
   
5. Statistical Methodology and Study Endpoints  ....................................................................... 1 1 
5.1 Statistical Methods Planned in the Protocol and Determination of Sample Size  ........ 11 
5.1.1 Statistical and Analytical Plans  ........................................................................ 1 1 
5.1.1.1 Common Conventions  ....................................................................... 1 1 
5.1.1.2 Demographics  .................................................................................... 15 
5.1.1.3 Efficacy Analyses  .............................................................................. 18 
   
   
   
5.1.2 Determination of Sample Size  ......................................................................... 27 
5.2 Changes in the Conduct of the Study or Planned Analyses  ......................................... 27 
5.2.1 Changes in the Conduct of the Study  ............................................................... 27 
5.2.2 Changes to Analyses Prior to Database Lock  .................................................. 27 
6. Data Handling and Analysis Conventions  ............................................................................. 27 
6.1 Study Treatment Conventions  ...................................................................................... 27 
6.1.1 Analysis Days  .................................................................................................. 27 
6.1.2 Missing/Incomplete Treatment End Date  ........................................................ 28 
6.2 Analysis Visit Windows  ............................................................................................... 28 
6.2.1 Efficacy ............................................................................................................ 28 
   
6.3 Site Pooling  .................................................................................................................. 29 
6.4 Missing/Incomplete Date Conventions  ........................................................................ 29 
6.4.1 Missing/Incomplete AE Start Date  .................................................................. 29 
6.4.2 Missing/Incomplete Me dication Start Date  ..................................................... 30 

6.4.3 Missing/Incomplete AE/Medication End Date  ................................................ 30 
6.5 Efficacy Endpoint Conventions  ................................................................................... 30  
6.6 Safety Endpoint Conventions  ....................................................................................... 30 
6.6.1 Adverse Events  ................................................................................................ 30 
6.6.1.1 Missing Intensity or Relationship  ...................................................... 30 
6.6.1.2 Possible Distant Spread of Toxin (PDSOT)  ...................................... 30 
6.6.1.3 AE Group of Interest ......................................................................... 30 
6.6.2 Clinical Laboratory Assessments  ..................................................................... 30 
6.6.3 Vital Signs  ........................................................................................................ 31 
6.6.3.1 Potentially Clinically Significant Criteria  ......................................... 31 
6.6.3.2 Continuous Descriptives and Shift Table Parameters  ....................... 31 
6.6.4 Electrocardiograms  .......................................................................................... 31 
6.7 Imputed Value Listing Conventions  ............................................................................. 31 
6.8 Analysis Plan Amendment 1 Summary  ....................................................................... 31 
 
2.1 List of Tables 
Table 3-1  Abbreviations and Definitions of Terms  ................................................................. 5 
Table 4-1  Study Objectives and Corresponding Endpoints  .................................................... 7 
   
Table 5-1  Analysis Populations  ............................................................................................. 1 1 
   
Table 5-3  Statistical Methodology  ........................................................................................ 14 
Table 5-4  Missing Data Handling by Endpoint Type ............................................................ 15 
Table 5-5  Analysis Population Summaries ........................................................................... 15 
Table 5-6  Subject Disposition Summaries  ............................................................................ 16 
Table 5-7  Protocol Deviation Summary  ................................................................................ 16 
Table 5-8  Demographic Summaries  ...................................................................................... 16 
Table 5-9  Baseline Characteristics Summaries  ..................................................................... 17 
Table 5-10  Medical History Summary  .................................................................................... 17 
Table 5-11  Medication Summaries  ......................................................................................... 17 

Table 5-12  NEI VFG-25 Summary  ......................................................................................... 18 
   
   
Table 5-15  Mesopic, High Contrast UNVA Analyses  ............................................................. 19 
   
   
   
   
   
   
   
Table 5-23  AE Terms  .............................................................................................................. 22 
   
Table 6-1  Analysis Day Definitions  ...................................................................................... 28 
   
   
Table 6-4  Imputation Scenarios  ............................................................................................ 29 
Table 6-5  Initial Imputed Date Algorithm  ............................................................................. 29 
Table 6-6  Missing AE Intensity and Rela tionship Imputation Algorithms  ........................... 30 
   
 
2.2 List of Figures 
   

3. List of Abbreviations and Definition of Terms 
Table 3-1 Abbreviations and Definitions of Terms 
Abbreviation/Term Definition 
AE adverse event 
AGN Allergan 
ANCOVA analysis of covariance 
ANOVA analysis of variance 
ATC Anatomical Therapeutic Chemical 
CFB change from baseline 
eCRF electronic case report form 
EO exploratory objective 
GCP Good Clinical Practice 
ICH International Conference on Harmonisation 
LOCF last observation carried forward 
LS least squares 
MedDRA Medication Dictionary for Regulatory Activities 
mITT modified intent-to-treat 
MMRM mixed-effects model for repeated measures 
NEI national eye institute (NEI) visual function questionnaire - 25 (VFQ-25) 
OC observed cases 
PCS potentially clinically significant 
PO primary objective 
PP per-protocol 
PRO patient reported outcome 
PT preferred term 
SAE serious adverse event 
SADE serious adverse device effect 
SAP statistical analysis plan 
SID subject identification 
SO secondary objective 
SOC system organ class 
TEAE treatment-emergent adverse event 
UDVA uncorrected distance vision acuity 
UNVA uncorrected near vision acuity 
VAS visual analog scale 
VFQ-25 visual function questionnaire - 25  
WHO World Health Organization 
4. Introduction 
This statistical analysis plan (SAP) details comprehensive, technical specifications of the 
statistical analyses of the efficacy and safety data outlined and/or specified in the final protocol 
of Study 199201-009 (version dated 2015-09-15) and the most recent amendment (version 4 
dated 2016-04-04). Specifications of tables, figures, and data listings are c ontained in a separate 
document.  
This document is organized into 3 main sections: 
1. Study overview 
2. Statistical Methodology and Study Endpoints 
3. Data Handling and Analysis Conventions 
 
4.1 Study Design Summary 
This study is a phase 2b, multicen ter, double-masked, parallel-group , randomized sequence, dose 
response, vehicle-controlled study  in patients with presbyopia.  Sixteen unfixed combination of 
AGN-190584  and AGN-199201 (  
and a fixed combination of AGN-190584  and AGN-199201  solutions will be 
dosed in the nondominant eye during 5 dosing periods .  For 17 different treatment combinations, 
each dosing period will be once daily for 2 consec utive days, followed by a 7 to 21 day washout 
before the next 2-day dosing period, until exit after the fifth 2-day dosing period.  The study 
duration will be 39 to 112 days per patient. 
Following a screening visit (days -18 to -1) patien ts will be randomized at a baseline visit (visit 
1) in a 1:1:1:1 ratio (stratified by uncorre cted near vision acuit y at baseline of ≤ 20/80 and > 
20/80) to 1 of the follo wing treatment groups:   
• Group 1:  AGN-199201  and AGN-190584 
vehicle 0% 
• Group 2:  AGN-199201  and AGN-190584 
ophthalmic solution   
• Group 3:  AGN-199201  and AGN-190584 
ophthalmic solution  
• Group 4:  AGN-199201  and AGN-190584 
ophthalmic solution    

All patien
 oph
for AGN
formulati
4.2 
Each stud
presented
Table 4-1 
Objectives
Primary 
PO1 To id
AGN-19
and AGN
dosed in improve
m
(UNVA) 
 nts will rec e
hthalmic sol u
-199201, a n
ion.   
Study
dy primary o
d with corre s
s 
dentify the o
9201 
N-190584
combinatio n
ment of unc o
in patients weive the fixe d
utions withi n
d the vehicl e
y Objectiv
objective (P O
sponding en d
Study Obje
ptimum co n
, 
 
n once a da y
orrected nea r
with presby od combinati o
n one of the 
e for fixed c
ves and En
O), seconda r
dpoint(s) be
ctives and Co
ncentrations o
 
when
y for the 
r vision acu i
opia on of AGN- 1
5 dosing pe r
ombination 
ndpoints 
ry objective 
low: 
rrespondin g E
 
of 
n 
ity 199201
riods.  Vehi c
ophthalmic 
(SO), and e x
Endpoints 
The prima
weighted a
baseline in
nondomin
between h
will be th e
dosing pe r and AG
cle for AGN -
solution ha v
xploratory o
Endpoints 
ary efficacy v
average cha n
n UNVA let t
nant eye ove r
hour 1 and h o
e hour 0 me a
riod. GN-190584 
-190584, ve h
ve the same 
objective (E O
variable is t h
nge from 
ter in the 
r 2-day peri o
our 10.  Bas e
asure for ea chicle 
O) is 
he 
ods 
eline 
ch 

4.3 Schedule of Activities 

5. Statistical Methodology and Study Endpoints 
5.1 Statistical Methods Planned in th e Protocol and Determination of 
Sample Size 
This statistical analysis plan (SAP) will be approved prior to database lock. The SAP expands the 
statistical section of the protocol and contains a detailed descrip tion of methods to analyze data 
collected in the study. The text portion of the SAP will be included in the CSR report as 
Appendix 16.1.9.  
5.1.1 Statistical and Analytical Plans 
Statistical analyses will be conducte d using  
5.1.1.1 Common Conventions 
5.1.1.1.1 Analysis Populations 
The analysis populations will consist of subjects as defined below: 
Table 5-1 Analysis Populations 
Population Definition Study Treatment 
Screened All screened subjects who sign informed consent — 
Modified Intent-to-
Treat (mITT) All randomized subjects with a baseline and at least 1 post baseline assessment of mesopic high contrast UNVA, with 
baseline vary not more than 3 lines across the 5 dosing period, 
and will be analyzed as randomized. Randomized assignment 
Per Protocol (PP) All randomized patients who have no significant protocol 
deviations that affect the primary efficacy variable and complete 
all study visits for each dosing period. Actual received 
Safety All subjects who received ≥ 1 administration of study treatment Actual received 
 
5.1.1.1.2 Study Treatments 
The following treatment groups are defined for this study: 
• AGN-199201  AGN-190584  
• AGN-199201 + AGN-190584  
• AGN-199201 + AGN-190584  
• AGN-199201  AGN-190584  
• Fixed Combo  + Fixed Combo  
• AGN-199201 0% + AGN-190584  
• AGN-199201 + AGN-190584  

• AGN-199201  + AGN-190584  
• AGN-199201 + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201 + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201  + AGN-190584  
• AGN-199201  + AGN-190584  
 
The following treatment sequences are defined for this study: 

5.1.1.1.3 Statistical Methodology 
The methodologies defined below apply as specifie d to individual endpoints defined in this SAP. 
When indicated, 95% two-sided confidence interv als and two-sided p-values will be presented. 

Individual endpoint analyses may specify excepti ons (additions or dele tions) to these general 
definitions. 
Table 5-3 Statistical Methodology 
Methodology Description 
M1 Categorical 
counts • Number of subjects in individual categories 
o Subjects with ≥ 1 qualifying event counted once per individual category 
M2 Categorical 
descriptives • Number and percentage of subjects in individual categories 
o Subjects with ≥ 1 qualifying event counted once per individual category 
• (Optional) N included if percentage denominator ≠ number of subjects in the 
population (standard percentage denominator). 
M3 PCS 
descriptives • Number and percentage of subjects meeting potentially clinically significant (PCS) criteria 
o Subjects with ≥ 1qualifying event counted once per PCS category  
• Percentage denominator = number of subjects with non-missing baseline and >=1 non-missing postbaseline assessment 
• Unevaluable assessments considered missing 
M4 Continuous 
descriptives • N included, mean, standard deviation (SD), median, minimum, maximum 
• N included = subjects with non-missing value 
M5 CFB 
descriptives • Continuous descriptives for baseline, postbaseline, and change from baseline (CFB) values 
• N included = subjects with non-missing values at both baseline and the specified postbaseline analysis visit 
M6 CFB ANCOVA • Continuous descriptives and standard error (SE) for baseline, postbaseline, and CFB values 
• Estimates derived from mixed model for CFB value controlling for factors (pilocarpine dose, oxymetazoline dose) and c ovariates (baseline UNVA severity, iris 
color) 
o Least squares (LS) means and standard errors 
o P-values from contrast t-test comparing active AGN- 199201 treatment 
groups vs AGN-199201 vehicle 
• N included = subjects with non-missing values at both baseline and the postbaseline analysis visit 
M7 CFB 
MMRM • Continuous descriptives and SE for baselin e, postbaseline, and CFB values at each 
analysis visit 
o N included = subjects with non-missing values at both baseline and the 
postbaseline analysis visit 
• Estimates derived from mixed model for CFB value controlling for fixed factors (pilocarpine dose, oxymetazoline dose,), co variates (baseline UNVA severity, iris 
color), and interactions (pilocarpine dose and oxymetazoline dose interaction), with an compound symmetry covariance matrix 
o LS means and standard errors 
o N included = subjects with non-missing values at both baseline and  postbaseline analysis visit 
M8 CFB figure • Plot of CFB LS means and SE bars for each treatment group. 
M9 CFB RS figure • Plot of CFB response surface in 3 dimension. 
M10 Responder • Categorical descriptives for responders and nonresponders 
o Nonresponders include: 
 Subjects who do not meet responder criteria 
CFB = change from baseline; ANCOVA = analysis of covariance; ANOVA = analysis of variance. MMRM = mixed model for repeated measures; RS=response surface 
 
Raw and derived data listings will be provided, an d will be fully defined in the table, figure, and 
data listing specification document. 
5.1.1.1.4 Missing Data 
General missing data handling conventions ar e specified for methodologies in Section 5.1.1.1.3 
and summarized as follows: 
Table 5-4 Missing Data Ha ndling by Endpoint Type 
Endpoint type Timing Missing Data Handling 
Responder Treatment Period • All subjects included 
• Subjects with no postbaseline values will be excluded 
CFB ANCOVA 
 Treatment Period • If missing covariates (including baseline if applicable)  
o Subject excluded 
• If missing weighted average change from baseline UNVA 
letters: 
o Subject excluded 
CFB MMRM Treatment Period • If missing covariates (including baseline if applicable) or missing values at all postbaseline analysis visits 
o Subject excluded 
• If missing weighted average change from baseline UNVA letters: 
o Subject excluded 
CFB Posebaseline Treatment Period • If missing value at the specified postbaseline analysis visit: 
o Available cases 
 Subject excluded 
 
5.1.1.1.5 Site Pooling 
Data from all sites will be pooled for analysis. 
5.1.1.1.6 Other Common Conventions 
Ocular adverse events and other ocular evaluations will be summarized using eye as the 
experimental unit by dosing group and dosing period.  Nonocular adverse events and other 
nonocular assessments will be summarized using patient as the experimental unit by dosing 
group and dosing period. 
5.1.1.2 Demographics 
5.1.1.2.1 Analysis Populations 
The distribution of subjects within the analys is populations will be summarized as follows: 
Table 5-5 Analysis Population Summaries 
Endpoint Description Timing Methodology 
Screened Population Distribution overall and within 
countries/regions/sites in total Screening Period, Categorical counts 
mITT, PP and Safety 
populations Distribution overall and within countries/regions/sites in total and by treatment group Treatment Period Categorical counts 
 
5.1.1.2.2 Subject Disposition 
Subject disposition encompasses the distribut ion of subjects who enter, complete, and 
discontinue each specified analysis period, al ong with eCRF-reported discontinuation reasons 
from each respective analysis period. Subject disposition will be summarized as follows: 
Table 5-6 Subject Disposition Summaries 
Endpoint Description Timing Methodology 
Screening and pretreatment disposition Distribution in the Screened Population in total Screening Period, 
Pretreament Period Categorical 
descriptives 
Study disposition Distribution in the mITT Population in 
total and by treatment group Treatment Period Categorical 
descriptives 
 
5.1.1.2.3 Protocol Deviations 
Protocol deviations will  be defined in a separate document, including importance classification. 
Protocol deviations will be summarized as follows: 
Table 5-7 Protocol Deviation Summary 
Endpoint Description Timing Methodology 
Important protocol deviations Distribution in the mITT Population in total and by treatment group Treatment Period Categorical 
descriptives 
 
5.1.1.2.4 Demographics 
Demographics will be summarized for the Screened Population, and in total and by treatment 
group for the mITT, PP and Safety populations, as follows: 
Table 5-8 Demographic Summaries 
Endpoint Description Timing Methodology 
Age Age (years) relative to informed consent 
date Informed consent Continuous 
descriptives 
Age group • 40-47 years 
• 48-51 years Informed consent Categorical 
descriptives 
Sex, race, and ethnicity • eCRF categories 
• Race group 
o White 
o Non-white 
• Ethnicity 
o Hispanic 
o Non-hispanic Screening Period Categorical 
descriptives 
 
5.1.1.2.5 Baseline Characteristics 
Baseline characteristics will be summarized in to tal and by treatment group for the mITT, PP and 
Safety populations as follows: 
Table 5-9 Baseline Characteristics Summaries 
Endpoint Description Timing Methodology 
Baseline characteristics • Iris color 
 Latest assessment in 
Screening Period or 
Pretreament Period Categorical 
descriptives 
Randomization strata • UNVA at baseline of ≤  20/80 
• UNVA at baseline of  > 20/80 Randomization date Categorical 
descriptives 
 
5.1.1.2.6 Medical History 
Medical history, encompassing abnormalities and surgeries reported as occurring before the 
Screening Visit, will be coded using the Medical  Dictionary for Regulat ory Activities (MedDRA), 
version 19.0 or newer. Unique subjects who report medical history events will be summarized by MedDRA system organ class (SOC) and preferred term (PT) in total and by treatment group for 
the Safety Population as follows: 
Table 5-10 Medical History Summary 
Endpoint Description Timing Methodology 
Medical history Abnormalities and surgeries occurring 
before the Screening Visit Screening Period Categorical 
descriptives 
SOCs will be sorted alphabetically; PTs will be sorted in descending frequency in the highest dose group. 
 
5.1.1.2.7 Prior and Concomitant Medications 
Medications will be listed for the Safety Population as follows: 
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version 14.0 or newer. Unique subjects who reported medications will be summarized by 
Anatomical Therapeutic Chemical (ATC) 4 class and PT in total and by treatment group for the 
Safety Population as follows: 
Table 5-11 Medication Summaries 
Endpoint Description Timing Methodology 
Prior medications Medications taken ≥ 1 time before the 
study treatment start date, regardless of 
medication end date 
 Screening Period, 
Pretreament Period Categorical 
descriptives 
Concomitant medications Medications taken ≥ 1 time on or after the 
study treatment start date, regardless of 
medication start date 
• Medications starting 1 day after  Treatment Period Categorical 
descriptives 
Endpoint Description Timing Methodology 
treatment end date will be listed 
but excluded from analysis 
ATC4 classes will be sorted alphabetically; PTs will be sorted in descending frequency in the highest dose group.  
5.1.1.2.8 National Eye Institute Visual Function Questionnaire 
National eye institute (NEI) visual function questionnaire - 25 (VFQ-25) that will be 
administered at screening to determine patien t-reported near and dist ance vision functioning. 
NEI VFQ-25 will be summarized for the Safety Population. 
Table 5-12 NEI VFG-25 Summary  
Endpoint Description Timing Methodology 
NEI VFQ-25 NEI VFQ-25 questionnaires Screening Period Categorical 
descriptives 
 
 
 
5.1.1.3 Efficacy Analyses 
Efficacy analyses will be based on the mITT Population.  The primary efficacy variable, 
weighted average change from baseline in UNVA le tter,  will also be analyzed based on the PP 
population. 
The following efficacy assessments are defined: 
: 

5.1.1.3.1 Study Success Criteria 
There will be no adjustment of type 1 error rate for the multiple tests.  
5.1.1.3.2 Mesopic, High Contrast UNVA  
General description of mesopic,  high contrast UNVA endpoints.  
Table 5-15 Mesopic, High Contrast UNVA Analyses 
Endpoint Description Timing Methodology 
Average change from 
baseline in UNVA letters (Primary efficacy 
variable) Average change from baseline in UNVA letters
1 in the 
nondominant eye over two-day dosing periods between 
hour 1 and hour 10.  Treatment 
Period CFB MMRM2  
CFB ANCOVA3 
CFB RS figure 
CFB figure 
 
  
  
 
   
  
 
  
  
 
  
  
 
 
  
 
 
 
  
  
 
 
  
 
 
 
  
  
 
  
   

5.1.1.4.2 Adverse Events 
The following adverse event (AE) terms are defined: 
Table 5-23 AE Terms 
Term Description 
Treatment-
emergent  An event that initially occurs or increases in inte nsity on or after the treatment start date, where: 
• Treatment start date ≤ event start date ≤ following washout period before the next 2-day 
dosing period or last dose date + 30 days 
On-therapy An event where: 
• Treatment start date ≤ event start date ≤ following washout period before the next 2-day 
dosing period or last dose date + 30 days 
 
AEs, encompassing abnormalities and surgeries repor ted as occurring after the Screening Visit, 
will be coded using MedDRA version 19.0 or newer. Unique subjects reporting AEs in the 

following AE categories will be summarized by treatment group and overall for the Safety 
Population as follows: 
Table 5-21 AE Summaries 
Endpoint Description Timing Methodology 
Overall summary Overall summary only for the following 
categories: 
• Treatment-emergent AEs 
(TEAEs) 
• Treatment-related TEAEs 
• Study-procedure-related TEAEs 
• On-therapy serious adverse events 
(SAEs) 
• On-therapy fatal SAEs 
• AEs leading to discontinuation Treatment Period, 
Follow-up Categorical 
descriptives 
TEAEs Overall summary and by SOC and PT Treatment Period, 
Follow-up Categorical 
descriptives 
Common TEAEs Summary by PT 
• Includes TEAEs occurring in ≥ 
5.0% of subjects in any treatment 
group Treatment Period, 
Follow-up Categorical 
descriptives 
TEAEs by intensity Overall summary and by SOC, PT, and 
intensity 
• Subjects categorized overall and within each SOC and PT for the most intense occurrence Treatment Period, 
Follow-up Categorical 
descriptives 
Treatment-related 
TEAEs Overall summary and by PT Treatment Period, 
Follow-up Categorical 
descriptives 
Study-procedure-related 
TEAEs Overall summary and by PT Treatment Period, 
Follow-up Categorical 
descriptives 
On-therapy SAEs1 Overall summary and by PT Treatment Period, 
Follow-up Categorical 
descriptives 
On-therapy fatal SAEs1 Overall summary and by PT Treatment Period, 
Follow-up Categorical 
descriptives 
AEs leading to study discontinuation
1 Overall summary and by PT Treatment Period, 
Follow-up Categorical 
descriptives 
1 Subjects who report ≥ 1 AE in the AE category and all AEs for those subjects will be listed. 
SOCs will be sorted alphabetically; PTs will be sorted in descending frequency in the highest dose group. 

5.1.1.5 Subgroup Analyses 
Subgroup analyses will be performed for the prim ary efficacy variable by UNVA severity at 
baseline  and iris color (brown or not brown). 
5.1.1.6 Interim Analyses 
Not applicable. 
5.1.2 Determination of Sample Size 
The study consists of 4 parallel groups and fort y patients per each parallel  group will be enrolled. 
With a 1:1:1:1 parallel group allocation and 10% dropout rate, a total of 160 patients are to be 
enrolled in order to have 144 patients complete th e study.  The sample size is deemed appropriate 
to assesses the efficacy profile of th e combination relative to monotherapies. 
5.2 Changes in the Conduct of the Study or Planned Analyses 
5.2.1 Changes in the Conduct of the Study 
Not applicable. 
5.2.2 Changes to Analyses Prior to Database Lock 
The term of  ‘average change from baseline in UNVA letters’ instead of ‘weighted average 
change from baseline in UNVA letters’ will be us ed since weighted average concept only applies 
when missing mid-timepoint values are imputed. UNVA responder analyses with at least a 2-line 
improvement in mesopic, high contrast UNVA from  baseline at a majority of postdose timepoints 
(6 or more) in the nondominant eye will be added. 
Subgroup analyses by gender, race and ethnicity will be performed .  
mITT definition will be change to ‘All randomized  subjects with a baseline and at least 1 post 
baseline assessment of mesopic high contrast UNVA,  with baseline vary not more than 3 lines 
across the 5 dosing period, and will be analyzed as randomized.’ 
6. Data Handling and Analysis Conventions 
6.1 Study Treatment Conventions 
6.1.1 Analysis Days 
Treatments are defined as follows: 
Table 6-1 Analysis Day Definitions 
Term Description 
Treatment Day Relative to treatment start date 
If analysis date ≥  treatment start date: 
• Day = analysis date – treatment start date + 1 
o Day 1 = treatment start date 
 
 
6.1.2 Missing/Incomplete Treatment End Date 
If the investigator is unable to provide the treatment end date, treatment end date will be imputed 
to the last available dosing record date /last available efficacy assessment date. 

  
  
  
6.3 Site Pooling 
Data from all sites will be pooled for analysis. 
6.4 Missing/Incomplete Date Conventions 
Dates may be imputed with year, month, and day values under certain scenarios: 
Table 6-4 Imputation Scenarios 
  Complete  
Scenario Year Month Day Imputable 
1 Yes Yes Yes Complete 
2 Yes Yes — Yes 
3 Yes — Yes No1 
4 Yes — — Yes 
5 — Yes Yes No1 
6 — Yes — No1 
7 — — Yes No1 
8 — — — Yes 
1 Not allowed per database design. 
 
Dates will be imputed initially toward a specified target date for imputable scenarios 2, 4, and 8, 
and adjusted against the latest reasonable dates. The initial imputed date is determined by the 
following algorithm:  
Table 6-5 Initial Imputed Date Algorithm 
Available Year Available Month (MM) 
(YYYY) Missing < Target Month = Target Month > Target Month 
Missing Target Date  —  
< Target Year YYYY-12-31  YYYY-MM-LD  
= Target Year Target Date YYYY-MM-LD Target Date YYYY-MM-01 
> Target Year YYYY-01-01  YYYY-MM-01  
YYYY = available start date year; MM = available start date month; LD = last day of the month. 
 
6.4.1 Missing/Incomplete AE Start Date 
AE start dates will be imputed as the minimum of the following: 
• Initial imputed date, where target date = Treatment start date 
• Complete end date 

6.4.2 Missing/Incomplete Medication Start Date 
Medication start dates will be imputed as the minimum of the following: 
• Initial imputed date, where target date = Treatment start date – 1 
• Complete end date 
6.4.3 Missing/Incomplete AE/Medication End Date 
AE and medication end dates will be imputed as the minimum of the following: 
• Initial imputed date, where target  date = Treatment end date + 30 
• Death date 
6.5 Efficacy Endpoint Conventions 
Not applicable. 
6.6 Safety Endpoint Conventions 
6.6.1 Adverse Events 
6.6.1.1 Missing Intensity or Relationship 
If the investigator is unable to provide the actual values, the following imputations will be 
applied: 
Table 6-6 Missing AE In tensity and Relationship Imputation Algorithms 
Missing Value Imputation Timing 
Intensity Mild Screening Pe riod, Pretreatment Period 
 Severe Treatment Period 
Relationship — Screening Period, Pretreatment Period 
 Related Treatment Period 
 
6.6.1.2 Possible Distant Spread of Toxin (PDSOT) 
Not applicable. 
6.6.1.3 AE Group of Interest 
Not applicable. 
6.6.2 Clinical Laboratory Assessments 
Not applicable 
6.7 Imputed Value Listing Conventions 
In general, listings will present the actual partial or missing values rather than the imputed values 
that may be used in endpoint derivation. In in stances where imputed values will be presented, 
imputed values will be flagged. Actual rules will be fully defined in the table, figure, and data listing specification document. 
 
6.8 Analysis Plan Amendment 1 Summary 
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section Revision Rationale 
Section 
5.1.1.1.1 mITT definition is changed to 
‘All randomized subjects 
with a baseline and at least 1 post baseline assessment of mesopic high contrast UNVA, with baseline vary not more than 3 lines across the 5 dosing period, and will be analyzed as randomized.’ Correction for the primary efficacy 
baseline data issue.  
Section Age group Correction 

Section Revision Rationale 
5.1.1.2.4 • 40-47 years 
• 48-51 years  
 
 
  
  
 
 
  
  
  
  
 
  
 
 
 
  
 
Section 5.2.2 UNVA responder analyses with 
at least a 2-line improvement in mesopic, high contrast UNVA from baseline at a majority of postdose timepoints (6 or more) in the nondominant eye will be added.
 Added additional analysis 
 
6.9 Analysis Plan Amendment 2 Summary 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section Revision Rationale 
 
  
  
 
 
 

ALLERGAN  
 
 
 
 
    
 
Date (DD/MMM/YYYY)/Time (PT)  Signed by:  Justification  
               
                         
                         
              
                  
                         
                         
                         
                         
                         
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 199201-009 Statistical Analysis Plan
